{
    "output": [
        [
            "Nuvo Pharmaceuticals Inc.",
            "COMP",
            "Acquire",
            "Resultz",
            "PRODUCT"
        ],
        [
            "Nuvo Pharmaceuticals Inc.",
            "COMP",
            "Operate_In",
            "Healthcare Sector",
            "SECTOR"
        ],
        [
            "Piedmont Pharmaceuticals LLC",
            "COMP",
            "Sell",
            "Resultz",
            "PRODUCT"
        ],
        [
            "Nuvo Pharmaceuticals Inc.",
            "COMP",
            "Fund",
            "US$7.0 million",
            "FIN_INSTRUMENT"
        ],
        [
            "Nuvo Pharmaceuticals Inc.",
            "COMP",
            "Assume",
            "Existing license agreements and partners",
            "ORG"
        ],
        [
            "Resultz",
            "PRODUCT",
            "Generate",
            "US$16.0 million net sales",
            "ECON_INDICATOR"
        ],
        [
            "Resultz",
            "PRODUCT",
            "Pay",
            "US$1.5 million royalties",
            "FIN_INSTRUMENT"
        ],
        [
            "Resultz",
            "PRODUCT",
            "Approved",
            "European Conformity CE mark",
            "REGULATION"
        ],
        [
            "Resultz",
            "PRODUCT",
            "Not_Yet",
            "Partnered or approved in most rest of world markets",
            "GPE"
        ],
        [
            "Nuvo Pharmaceuticals Inc.",
            "COMP",
            "Manufacture",
            "Resultz",
            "PRODUCT"
        ],
        [
            "Nuvo Pharmaceuticals Inc.",
            "COMP",
            "Produce",
            "At Nuvo\u2019s Varennes, Qu\u00e9bec manufacturing site",
            "FACILITY"
        ],
        [
            "Nuvo Pharmaceuticals Inc.",
            "COMP",
            "Purchase",
            "Global, ex-U.S. rights to Resultz",
            "PRODUCT"
        ],
        [
            "Nuvo Pharmaceuticals Inc.",
            "COMP",
            "Pay",
            "Single-digit royalty on non-Royalty Markets net sales through 2023",
            "FIN_INSTRUMENT"
        ],
        [
            "Nuvo Pharmaceuticals Inc.",
            "COMP",
            "Potential_Added",
            "Future consideration in the form of payments for achieving certain aggregate annual net sales-based milestones",
            "FIN_INSTRUMENT"
        ],
        [
            "Stifel, Nicolaus & Company, Incorporated",
            "COMP",
            "Act",
            "As exclusive financial advisor to Piedmont Pharmaceuticals LLC",
            "SERVICE"
        ]
    ]
}